Ivy Brain Tumor Center Initiates Phase 0 Clinical Trial with BeiGene for Newly Diagnosed and Recurrent Glioblastoma

The Ivy Brain Tumor Center at Barrow Neurological Institute announced the opening of a Phase 0 clinical trial for patients with newly diagnosed and recurrent glioblastoma to evaluate pamiparib, an investigational small molecule PARP inhibitor from BeiGene.